Iran launches second production line of COVIran Barekat vaccine
Iran has launched the second production line of the COVIran Barekat vaccine, developed by experts at the Headquarters for Executing the Order of Imam Khomeini (God's mercy upon him).
According to Press TV, Hassan Jalili, Director of the research team and CEO of Shifa Pharmed Company, said on Saturday that the second industrial phase of COVIran Barekat vaccine started last week.
“In the coming days, the first consignment produced on this line by the scientists of the Barkat Pharmaceutical Group will be secured, and the second phase will be officially operational,” he added.
The new line can produce 6 to 8 million doses of the coronavirus vaccine a month, creating a new capacity in Iran's vaccination program, Jalili said.
So far, Jalili said, about 10 million doses of the COVIran Barekat vaccine have been manufactured on the first line, 5.2 million doses of which have been delivered to the Health Ministry after quality control tests.
The remaining vaccines will be gradually delivered to the Ministry for inoculation at public vaccination centers.
Jalili also said the installation of machinery and equipment for the third production line of the plant is diligently underway.
“In the coming weeks, we will announce good news about the launch of the third phase in production of the COVIran Barekat vaccine and the capacity to produce more than 20 million doses per month.”
Iran has so far administered nearly 34 million doses of COVID-19 vaccines, including more than 11.7 million who have received two shots. They have been either domestically produced or imported from abroad despite illegal US sanctions.